Skip to main content
  • Book
  • © 2015

Targeted Therapy of Acute Myeloid Leukemia

Editors:

(view affiliations)
  • Presents updated contemporary classification systems of myeloid leukemias, their genetic defects and the proteomic alterations characteristic of acute myeloid leukemia

  • Summarizes and interprets targeted in acute myeloid therapies, along with future therapeutics

  • Serves as a useful guideline to scientists, translational researchers and clinicians in the field

  • Includes supplementary material: sn.pub/extras

Part of the book series: Current Cancer Research (CUCR)

Buying options

eBook
USD 169.00
Price excludes VAT (USA)
  • ISBN: 978-1-4939-1393-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD 219.99
Price excludes VAT (USA)
Hardcover Book
USD 219.99
Price excludes VAT (USA)

This is a preview of subscription content, access via your institution.

Table of contents (44 chapters)

  1. Front Matter

    Pages i-xix
  2. Genetics and Classification of Acute Myeloid Leukemia

    • Alison R. Walker, Guido Marcucci
    Pages 1-25
  3. Apoptosis

    1. Front Matter

      Pages 45-45
    2. Bcl-2 Family: Translational Aspects

      • Prithviraj Bose, Steven Grant
      Pages 67-94
    3. IAP Family of Proteins as Therapeutic Targets for Acute Myeloid Leukemia

      • Bing Z. Carter, Michael Andreeff
      Pages 95-121
    4. TP53 Mutations in Acute Myeloid Leukemia

      • Ulrike Bacher, Claudia Haferlach, Vera Grossmann, Susanne Schnittger, Torsten Haferlach
      Pages 123-133
    5. Targeting p53 Tumor Suppressor for AML Therapy

      • Kojima Kensuke, Lyubomir T. Vassilev
      Pages 135-150
  4. Signaling

    1. Front Matter

      Pages 175-175
    2. PIM Kinases in AML

      • Lisa S. Chen, Varsha Gandhi
      Pages 177-199
    3. Development of Midostaurin as a Tyrosine Kinase Inhibitor

      • Gabriela Motyckova, Richard M. Stone
      Pages 201-214
    4. FLT3 in AML

      • Naval Daver, Farhad Ravandi
      Pages 215-231
    5. FLT3-ITD. Clinical (Sorafenib/AC220)

      • Naveen Pemmaraju, Jorge Eduardo Cortes
      Pages 233-249
    6. Nucleophosmin (NPM1)

      • Ramesh Balusu, Warren Fiskus, Kapil N. Bhalla
      Pages 251-273
    7. Raf/MEK/ERK Signaling

      • James A. McCubrey, Linda S. Steelman, Jörg Bäsecke, Alberto M. Martelli
      Pages 275-305
    8. Clinical Use of Farnesyltransferase Inhibitors

      • Chezi Ganzel, Jacob M. Rowe
      Pages 325-333
    9. The PI3K-AKT-mTOR Signaling Network in AML

      • Brandon Beagle, David A. Fruman
      Pages 335-362

About this book

This book provides an unprecedented overview of targeted therapies for acute myeloid leukemias. The volume provides comprehensive coverage of the diverse therapeutic strategies that have been developed during the last decade and are now being evaluated in early clinical trials. Authoritative chapters are written by leading research scientists and clinicians, who explain basic concepts and the clinical translation of topics that include the underlying genetic and proteomic abnormalities of AML. The chapter topics include the development of novel nucleoside analogues, the roles of microRNAs, apoptosis regulators Bcl-2 and p53, and of critical cell signaling proteins such as PIM, FLT3, Raf/MEK, PI3K/AKT/mTOR and aurora kinases. In addition, chapters on epigenetic mechanisms, nuclear receptors, cell surface antigens, the hypoxic leukemia microenvironment, stem cells, and leukemia metabolism, provide insight into leukemia cell vulnerabilities. Cell therapies utilizing T-, NK- and mesenchymal stem cells and progress in hematopoietic transplantation strategies complete the overview of the multi-dimensional therapeutic landscape, where  leukemia specialists develop treatment strategies, which are expected to bring forth critical breakthroughs in the field of leukemia. 

Keywords

  • AML
  • acute myeloid leukemia
  • apoptosis
  • mutation
  • targeted therapy

Editors and Affiliations

  • Dept. Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA

    Michael Andreeff

Bibliographic Information

  • Book Title: Targeted Therapy of Acute Myeloid Leukemia

  • Editors: Michael Andreeff

  • Series Title: Current Cancer Research

  • DOI: https://doi.org/10.1007/978-1-4939-1393-0

  • Publisher: Springer New York, NY

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer-Verlag New York 2015

  • Hardcover ISBN: 978-1-4939-1392-3

  • Softcover ISBN: 978-1-4939-3989-3

  • eBook ISBN: 978-1-4939-1393-0

  • Series ISSN: 2199-2584

  • Series E-ISSN: 2199-2592

  • Edition Number: 1

  • Number of Pages: XIX, 826

  • Number of Illustrations: 16 b/w illustrations, 46 illustrations in colour

  • Topics: Cancer Biology, Pharmacology, Cell Biology, Microbiology

Buying options

eBook
USD 169.00
Price excludes VAT (USA)
  • ISBN: 978-1-4939-1393-0
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD 219.99
Price excludes VAT (USA)
Hardcover Book
USD 219.99
Price excludes VAT (USA)